Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 183

1.

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.

Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW.

N Engl J Med. 2010 Oct 28;363(18):1704-14. doi: 10.1056/NEJMoa1008410. Epub 2010 Aug 29.

PMID:
20979470
[PubMed - indexed for MEDLINE]
Free Article
2.

CYP2C19 genotype and outcomes of clopidogrel treatment.

Geisler T, Bigalke B, Schwab M.

N Engl J Med. 2011 Feb 3;364(5):481; author reply 482. doi: 10.1056/NEJMc1013331#SA1. No abstract available.

PMID:
21288102
[PubMed - indexed for MEDLINE]
3.

Cytochrome p-450 polymorphisms and response to clopidogrel.

Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS.

N Engl J Med. 2009 Jan 22;360(4):354-62. doi: 10.1056/NEJMoa0809171. Epub 2008 Dec 22.

PMID:
19106084
[PubMed - indexed for MEDLINE]
Free Article
4.

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.

Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC; PLATO investigators.

Lancet. 2010 Oct 16;376(9749):1320-8. doi: 10.1016/S0140-6736(10)61274-3.

PMID:
20801498
[PubMed - indexed for MEDLINE]
5.

CYP2C19 genotype and outcomes of clopidogrel treatment.

Siasos G, Tousoulis D, Stefanadis C.

N Engl J Med. 2011 Feb 3;364(5):481-2. doi: 10.1056/NEJMc1013331#SA2. No abstract available.

PMID:
21288101
[PubMed - indexed for MEDLINE]
6.

The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome.

Frére C, Cuisset T, Gaborit B, Alessi MC, Hulot JS.

J Thromb Haemost. 2009 Aug;7(8):1409-11. doi: 10.1111/j.1538-7836.2009.03500.x. Epub 2009 May 30. No abstract available.

PMID:
19496924
[PubMed - indexed for MEDLINE]
7.

Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.

Fuster V, Sweeny JM.

JAMA. 2010 Oct 27;304(16):1839-40. doi: 10.1001/jama.2010.1566. No abstract available.

PMID:
20978263
[PubMed - indexed for MEDLINE]
8.

Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis.

Liu YP, Hao PP, Zhang MX, Zhang C, Gao F, Zhang Y, Chen YG.

Thromb Res. 2011 Dec;128(6):593-4. doi: 10.1016/j.thromres.2011.07.003. Epub 2011 Jul 27. No abstract available.

PMID:
21794898
[PubMed - indexed for MEDLINE]
9.

Genetic determinants of response to clopidogrel and cardiovascular events.

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators.

N Engl J Med. 2009 Jan 22;360(4):363-75. doi: 10.1056/NEJMoa0808227. Epub 2008 Dec 22.

PMID:
19106083
[PubMed - indexed for MEDLINE]
Free Article
10.

Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome.

Cuisset T, Quilici J, Cohen W, Fourcade L, Saut N, Pankert M, Gaborit B, Carrieri P, Morange PE, Bonnet JL, Alessi MC.

Am J Cardiol. 2011 Sep 15;108(6):760-5. doi: 10.1016/j.amjcard.2011.05.045. Epub 2011 Jul 30.

PMID:
21803320
[PubMed - indexed for MEDLINE]
11.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
[PubMed - indexed for MEDLINE]
12.

Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.

Desai NR, Canestaro WJ, Kyrychenko P, Chaplin D, Martell LA, Brennan T, Matlin OS, Choudhry NK.

Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):694-9. doi: 10.1161/CIRCOUTCOMES.113.000321. Epub 2013 Nov 5.

PMID:
24192573
[PubMed - indexed for MEDLINE]
13.

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS.

JAMA. 2010 Oct 27;304(16):1821-30. doi: 10.1001/jama.2010.1543.

PMID:
20978260
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome.

Brackbill ML, Kidd RS, Abdoo AD, Warner JG Jr, Harralson AF.

Heart Vessels. 2009 Mar;24(2):73-8. doi: 10.1007/s00380-008-1085-2. Epub 2009 Apr 1.

PMID:
19337788
[PubMed - indexed for MEDLINE]
15.

The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients.

Li Y, Tang HL, Hu YF, Xie HG.

J Thromb Haemost. 2012 Feb;10(2):199-206. doi: 10.1111/j.1538-7836.2011.04570.x. Review.

PMID:
22123356
[PubMed - indexed for MEDLINE]
16.

Clopidogrel in acute coronary syndrome: to genotype or not?

Storey RF.

Lancet. 2009 Jan 24;373(9660):276-8. doi: 10.1016/S0140-6736(08)61846-2. Epub 2008 Dec 26. No abstract available.

PMID:
19108882
[PubMed - indexed for MEDLINE]
17.

CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.

Peters BJ, Harmsze AM, ten Berg JM, Maitland-van der Zee AH, Tjoeng MM, de Boer A, Deneer VH.

Pharmacogenomics. 2011 Feb;12(2):141-4. doi: 10.2217/pgs.10.211. No abstract available.

PMID:
21332306
[PubMed - indexed for MEDLINE]
18.

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A.

Circulation. 2010 Feb 2;121(4):512-8. doi: 10.1161/CIRCULATIONAHA.109.885194. Epub 2010 Jan 18.

PMID:
20083681
[PubMed - indexed for MEDLINE]
Free Article
19.

Current status of clopidogrel pharmacogenomics.

Giusti B, Gori AM, Marcucci R, Abbate R.

Pharmacogenomics. 2012 Nov;13(15):1671-4. doi: 10.2217/pgs.12.153. No abstract available.

PMID:
23171330
[PubMed - indexed for MEDLINE]
20.

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2008 May 20;51(20):1925-34. doi: 10.1016/j.jacc.2007.12.056.

PMID:
18482659
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk